ItalyItaly

Establishing a world-class translational cancer center

14.07.2009

Madrid – Spain has started an offensive to cut the time from bench to clinic. In mid-June, Science Minister Cristina Garmendia signed a contract with President of Madrid Esperanza Aguirre and Mariano Barba­cid, the director of Spain’s National Cancer Center (CNIO) to establish a new CNIO “Clinical Research Programme” at the Madrid-based hospital of Fuenlabrada. The programme, which will be led by Manuel Hidalgo from John Hopkins Hospital (Baltimore), a specialist in gastrointestinal cancer, will focus on translational cancer research – the transfer of experimental therapies from animal models to patients.
To accomplish this, three units – a clinical research unit in which new drugs can be tested on 1,500 patients per year, a diagnostic imaging unit and a cancer genomics unit – will work with researchers from the CNIO. One goal will be to identify and clinically validate biomarkers that indicate cancer disease progression. That could in turn offer novel cancer approaches to late-stage cancer patients, and optimise chemotherapy and targeted therapies to individuals. Another goal will be to identify relevant cancer genes by high-throughput sequencing of patient DNA in order to find novel pathways that could be targeted by small molecules or biologicals.
Barbacid said that the programme is “a pioneer in Spain” and that it would make Fuenlabrada one of the world’s top-10 centres for preclinical cancer research. In its five-year strategic plan, the CNIO has defined the goals of its new clinical units there for the design, implementation and analysis of Phase I and II clinical studies with novel anti-tumorigenic agents. The center wants to hire researchers with a focus on late preclinical drug development, pharmacokinetics, biomarker discovery and molecular imaging, and also join forces with external research groups. In a first sucess, German oncologist Christopher Heeschen from the University Munich has agreed to coordinate a group examining cancer stem cells in order to develop strategies to destroy them.
Initial funding will come from Spain’s Ministries of Science and Innovation, Health and Social Policy as well as Madrid’s health authorities. The Caja Madrid foundation will donate state-of-the-art equipment to the project.

ItalyItaly

07.03.2012

Toscana Biomarkers S.r.l has entered the market for biomarkers with its first diagnostic kit. In late January, the company from Siena signed a licence agreement with DIESSE Ricerche S.r.l, based in Genoa. DIESSE will produce and...

ItalyItaly

07.03.2012

Italian researchers have reprogrammed neonatal cardiomyocytes into iPSCs that can re-differentiate toward CMs more efficiently than either cardiac fibroblast-derived iPS cells or even ES cells. (Cell Death Differ.,...

ItalyItaly

09.01.2012

Rome – A cold virus isolated from chimpanzees might work as an vector for human vaccines. Adenoviruses are principally suitable as vectors for vaccines for their ability to induce strong immune responses. But as most humans have...

ItalyItaly

16.12.2011

Milan/Turku – Italian drug developer Newron SpA has had a roller-coaster ride in the last few months. First Merck Serono decided to drop its stake in the company’s Parkinson’s Disease candidate salfinamide, and returned the...

ItalyItaly

15.12.2011

Genoa/Irvine – Researchers from the universities at Genoa and Irvine (US) have patented a new compound that blocks removal of the endo­cannabinoid painkiller anandamide from the synaptic space by a selective transport system....

ItalyItaly

01.10.2011

Parma/Baranzate – Chiesi Farmaceutici Spa has said it will lengthen its long-term collaboration with NiKem Research, which is focused on developing treatments within the respiratory therapeutic area. The two drug developers have...

ItalyItaly

01.10.2011

Milan/Turku – Biotie Therapies ASA’s announcement that it had signed an agreement to acquire Newron Pharma­ceuticals S.p.A. for €45m is both good and bad news for the Italian biotechnology sector. While Italy is losing one of its...

ItalyItaly

19.08.2011

Como – Shares in Gentium SpA lost about a third of their value on Thursday after The Italian biopharmaceutical company withdrew a marketing application for its drug Defibrotide being used against complications related to stem...

ItalyItaly

01.08.2011

Milan/London – Italy’s MolMed SpA has signed a deal with UK-based pharmaceutical giant GlaxoSmithKline to develop a production process for a gene therapy against the rare ‘bubble boy disease’. Over the next two years, GSK will...

Displaying results 1 to 10 out of 181

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-italy/article/establishing-a-world-class-translational-cancer-center.html

Events

All Events

Stock list

All quotes

TOP

  • ADDEX3.30 CHF6.45%
  • PAION3.17 EUR3.93%
  • SANTHERA90.75 CHF3.07%

FLOP

  • WILEX2.36 EUR-12.27%
  • THERAMETRICS0.08 CHF-11.11%
  • CYTOS0.23 CHF-4.17%

TOP

  • CO.DON3.27 EUR30.8%
  • PAION3.17 EUR27.8%
  • EPIGENOMICS3.80 EUR22.6%

FLOP

  • MEDIGENE3.82 EUR-17.8%
  • ADDEX3.30 CHF-17.5%
  • EVOTEC3.10 EUR-15.5%

TOP

  • SANTHERA90.75 CHF2124.3%
  • CO.DON3.27 EUR255.4%
  • PAION3.17 EUR213.9%

FLOP

  • CYTOS0.23 CHF-94.3%
  • THERAMETRICS0.08 CHF-42.9%
  • BIOFRONTERA2.18 EUR-40.3%

No liability assumed, Date: 22.09.2014


Current issue

All issues

Product of the week

Products